Ensysce Biosciences discloses $77.2 million private securities offering
A Form D filing shows the company sold equity tied to a business combination transaction, with 44 investors participating.
Ensysce Biosciences, Inc., based in La Jolla, California, filed a Form D notice with the Securities and Exchange Commission disclosing a private securities offering. The filing lists a date of first sale of August 5, 2026, and is marked as a new notice.1
The offering totaled $77,200,000, with the total amount sold matching the total offering amount and $0 remaining to be sold. Of the total amount sold, $38.6 million is subject to certain contingencies.1
The securities offered included equity and a security to be acquired upon exercise of an option, warrant or other right to acquire security, and the offering was made in connection with a business combination transaction such as a merger, acquisition or exchange offer.1
The filing indicates a total of 44 investors have already invested in the offering.1 Sales commissions were reported at $1,289,946, estimated, and finders' fees at $200,000, also estimated.1
The recipients associated with the offering listed in the filing were UBS Securities LLC and Cantor Fitzgerald & Co., both based in New York.1
The company claimed exemption under Rule 506(b) of Regulation D.1
Related persons listed in the filing include Lynn D. Kirkpatrick, Bob Gower, William Chang, Steve Martin, Adam Levin, David Humphrey and James Morrison, all associated with the company's La Jolla address.1
The notice was signed by Dr. Lynn Kirkpatrick, identified as CEO, dated August 20, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.